This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. People taking medicines to control their HIV infection normally take at least 3 of these medicines at the same time. For example, a combination might be 2 nucleoside reverse transcriptase inhibitors (NRTI's) and a protease inhibitor. There are several small studies that suggest using a protease inhibitor combined with a low amount of ritonavir (Norvir), another protease inhibitor, can control HIV infection without using other HIV drugs. The main purpose of this research study is to see if taking atazanavir (Reyataz), a protease inhibitor, combined with a low amount of ritonavir will control HIV infection without using other HIV drugs. This study will also see if this treatment is safe in treating HIV infection and if there are any side effects when using atazanavir with ritonavir. Atazanavir and ritonavir are approved by the U.S. Food and Drug Administration (FDA) for use with other HIV drugs in the treatment of HIV infection. Atazanavir with ritonavir is not approved for use without other HIV drugs.
Showing the most recent 10 out of 1065 publications
